Dr. Mody’s primary research interest is in development of new drugs against childhood cancers. He is the Principal Investigator of International Phase-II, randomized trial of Chimeric 14.18 or Temsirolimus in combination with Irinotecan/ Temozolomide by the Children’s Oncology Group (COG). He is also conducting a Phase-I trial of Bortezomib in combination with Irinotecan in refractory / relapsed neuroblastoma. He is a member of the High Risk Neurobalstoma Committee of COG and is the Principle Investigator of the Children's Oncology Group, Phase-I/ Phase II-III Consortium studies at C.S. Mott Children's Hospital.
Dr. Mody is also investigating role Precision Medicine in Pediatric Oncology through Next Generation Sequencing (NGS) in collaboration with the laboratory of Dr. Arul Chinnaiyan in the Michigan Center of Translational Pathology (MCTP).
Dr. Mody’s other interests include health related outcomes of childhood cancer survivors.